Healthcare utilization following cognitive-behavioral treatment for panic disorder with agoraphobia

Cognitive Behaviour Therapy

Volumn 34, Issue 2, 2005, Pages 79-88

  Roberge, Pasquale ^a   Marchand, André ^a   Reinharz, Daniel ^b   Cloutier, Karine ^a   Mainguy, Nicole ^c   Miller, Jean Marc ^c   Bégin, Jean ^a   Turcotte, Julie ^d  

^a UNIVERSITÉ DU QUÉBEC À MONTRÉAL   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c CENTRE DE RECHERCHE FERNAND SEGUIN   (Canada)

^d HÔPITAL DU SACRÉ COEUR DE MONTRÉAL   (Canada)

Author keywords

Anxiety disorders; Cognitive behavior therapy; Cost study; Healthcare costs; Medication; Panic disorder with agoraphobia; Psychotherapy

Indexed keywords

ADULT; AGED; AGORAPHOBIA; ARTICLE; BEHAVIOR THERAPY; COGNITIVE THERAPY; COMORBIDITY; CONTROLLED STUDY; COST CONTROL; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; EMPIRICISM; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HUMAN; INTERVIEW; MAJOR CLINICAL STUDY; MALE; MEDICAL CARE; MENTAL HEALTH CARE; NONPARAMETRIC TEST; PANIC; RELAPSE;

ADULT; AGED; AGORAPHOBIA; ANALYSIS OF VARIANCE; COGNITIVE THERAPY; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HEALTH SERVICES; HUMANS; MALE; MIDDLE AGED; PANIC DISORDER; QUEBEC; STATISTICS, NONPARAMETRIC;

EID: 21044438013     PISSN: 16506073     EISSN: None     Source Type: Journal    
DOI: 10.1080/16506070510008443     Document Type: Article

References (39)

1. American Psychiatric Association (1994). Diagnostic and Statistical Manual of Mental Disorders (4th edn). Washington, DC: American Psychiatric Association.
2. Bandelow, B. (1995). Assessing the efficacy of treatments for panic disorder and agoraphobia: II. The Panic and Agoraphobia Scale. International Clinical Psychopharmacology, 10, 73-81.
3. Beck, A. T., Rush, A. J., Shaw, B. F., & Emery, G. (1979). Cognitive Therapy of Depression. New York: Guilford Press.
4. Bowen, R. C., D'Arcy, C., South, M. N., & Hawkes, J. E. (1990). The effects of a nurse therapist conducted behavioral agoraphobia treatment program on medical utilization. Journal of Anxiety Disorders, 4, 341-349.
5. Buller, R., Winter, P., Amering, M., Katschnig, H., Lavori, P. W., Deltito, J. A., & Klerman, G. L. (1992). Center differences and cross-national invariance in help-seeking for panic disorder: A report from the cross-national collaborative panic study. Social Psychiatry and Psychiatric Epidemiology, 27, 135-141.
6. Chambless, D. L., Caputo, G. C., Bright, P., & Gallagher, R. (1984). Assessment of fear of fear in agoraphobics: The Body Sensations Questionnaire and the Agoraphobic Cognitions Questionnaire. Journal of Consulting and Clinical Psychology, 52, 1090-1097.
7. Chambless, D. L., Caputo, G. C., Jasin, S. E., Gracely, E. J., & Williams, C. (1985). The Mobility Inventory for Agoraphobia. Behaviour Research and Therapy, 23, 35-44.
8. Collins, K. A., Westra, H. A., Dozois, D. J. A., & Burns, D. D. (2004). Gaps in accessing treatment for anxiety and depression: challenges for the delivery of care. Clinical Psychology Review, 24, 583-616.
9. Di Nardo, P. A., Brown, T., & Barlow, D. H. (1994). Anxiety Disorders Interview Schedule-IV. Albany, NY: Greywind.
10. Duquette, R. L., Dupuis, G., & Perrault, J. (1994). A new approach for quality of life assessment in cardiac patients: rationale and validation of the Quality of Life Systemic Inventory. Canadian Journal of Cardiology, 10, 106-112.
11. Fava, G. A., Rafanelli, C., Grandi, S., Conti, S., Ruini, C., Mangelli, L., & Belluardo, P. (2001). Long-term outcome of panic disorder with agoraphobia treated by exposure. Psychological Medicine, 31, 891-898.
12. Gauthier, J. G., Morin, C., Thériault, F., & Lawson, J. S. (1982). Adaptation française d'une mesure d'auto-évaluation de l'intensité de la dépression. Revue Québécoise de Psychologie, 3, 13-27.
13. Gould, R. A., Otto, M. W., & Pollack, M. H. (1995). A meta-analysis of treatment outcome for panic disorder. Clinical Psychology Review, 15, 819-844.
14. Hofmann, S. G., & Barlow, D. H. (1999). The costs of anxiety disorders: implications for psychosocial interventions. In N. E. Miller, K. M. Magruder (Eds), Cost-effectiveness of Psychotherapy (pp. 224-234). New York: Oxford University Press.
15. Kashner, T. M., & Rush, A. J. (1999). Measuring medical offsets of psychotherapy. In N. E. Miller, K. M. Magruder (Eds), Cost-Effectiveness of Psychotherapy (pp. 109-121). New York: Oxford University Press.
16. Katon, W. J., Von Korff, M., & Lin, E. (1992). Panic disorder: relationship to high medical utilization. American Journal of Medicine, 92(suppl. 1A), 7S-11S.
17. Kessler, R. C., McGonagle, K. A., Zhao, S., Nelson, C. B., Hugues, M., Eshleman, S., Wittehen, H. U., & Kendler, K. S. (1994). Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States: results from the National Comorbidity Survey. Archives of General Psychiatry, 51, 8-19.
18. Klerman, G. L., Weissman, M. M., Ouellette, R., Johnson, J., & Greenwald, S. (1991). Panic attacks in the community: social morbidity and health care utilization. Journal of the American Medical Association, 265, 742-746.
19. Lave, J. R., Frank, R. G., Schulberg, H. C., & Kamlet, M. S. (1998). Cost-effectiveness of treatments for major depression in primary care practice. Archives of General Psychiatry, 55, 645-651.
20. Levesque, J.-F., & Bergeron, P. (2003). Quebec's health care system: origins, organization, and future. In C. P. Shah (Ed.), Public Health and Preventive Medicine in Canada (5th edn). Toronto: Elsevier.
21. Mavissakalian, M., Michelson, L., Greenwald, D., Kornblith, S., & Greenwald, M. (1983). Cognitive-behavioral treatment of agoraphobia: paradoxical intention vs. self-statement training. Behaviour Research and Therapy, 21, 75-86.
22. Mumford, E., Schlesinger, H. J., Glass, G. V., Patrick, C., & Cuerdon, T. (1984). A new look at evidence about reduced cost of medical utilization following mental health treatment. American Journal of Psychiatry, 141, 1145-1158.
23. Otto, M. W., Hong, J. J., & Safren, S. A. (2002). Benzodiazepine discontinuation difficulties in panic disorder: conceptual model and outcome for cognitive-behavior therapy. Current Pharmaceutical Design, 8, 75-80.
24. Rees, C. S., Richards, J. C., & Smith, L. M. (1998). Medical utilization and costs in panic disorder: a comparison with social phobia. Journal of Anxiety Disorders, 12, 421-435.
25. Reiss, S., Peterson, R. A., Gursky, D. M., & McNally, R. J. (1986). Anxiety sensitivity, anxiety frequency and the prediction of fearfulness. Behaviour Research and Therapy, 24, 1-8.
26. Roberge, P., Marchand, L., Grenier, S., & Marchand, A. (2003). Validation de l'Échelle d'évaluation de la panique et de l'agoraphobie. Revue canadienne des sciences du comportement, 35, 61-66.
27. Roberge, P., Marchand, A., Reinharz, D., Dupuis, G., Mainguy, N., Savard, P., & Landry, P. Cognitive-Behavioral Treatment for Panic Disorder with Agoraphobia: A Randomized Controlled Trial and Cost-Effectiveness Analysis. Manuscript submitted for publication.
28. Roy-Byrne, P. P., Stein, M. B., Russo, J., Mercier, E., Thomas, R., McQuaid, J., Katon, W. J., Craske, M. G., Bystritsky, A., & Sherbourne, C. D. (1999). Panic disorder in the primary care setting: comorbidity, disability, service utilization, and treatment. Journal of Clinical Psychiatry, 60(7), 492-499.
29. Salvador-Carulla, L., Segui, J., Fernandez-Cano, P., & Canet, J. (1995). Costs and offset effect in panic disorders. British Journal of Psychiatry, 166(suppl. 27), 23-28.
30. Siegel, S., & Castellan, N. J. (1988). Nonparametric Statistics for the Behavioural Sciences (2nd edn). McGraw-Hill: New York.
31. Siegel, L., Jones, W. C., & Wilson, J. O. (1990). Economic and life consequences experienced by a group of individuals with panic disorder. Journal of Anxiety Disorders, 4, 201-211.
32. Stephenson, R., Marchand, A., & Lavallée, M.-C. (1997). Validation de l'Inventaire de mobilité pour l'agoraphobie auprès de la population québéoise francophone. Science et Comportement, 26, 35-58.
33. Stephenson, R., Marchand, A., & Lavallée, M.-C. (1998). Validation du questionnaire des sensations physiques auprès de la population Canadienne française. Encéphale, 24, 415-425.
34. Stephenson, R., Marchand, A., & Lavallée, M.-C. (1999). A French Canadian adaptation of the Agoraphobic Cognitions Questionnaire: cross-cultural validation and gender differences. Scandinavian Journal of Behavior Therapy, 28, 1-12.
35. Stephenson, R., Marchand, A., Lavallée, M.-C., & Brillon, P. (1996). Translation and transcultural validation on the Sensibility Anxiety Index. Proceedings of the 26th Meeting of the International Congress of Psychology. Montreal, Canada, 31 (3-4), No. 484.104.
36. Swinson, R. P., Cox, B. J., & Woszczyna, C. B. (1992). Use of medical services and treatment for panic disorder with agoraphobia and for social phobia. Canadian Medical Association Journal, 147, 878-883.
37. Von Korff, M., Katon, W., & Lin, E. (1990). Psychological distress, physical symptoms, utilization and the cost-offset effect. In N. Sartorius, D. Goldberg, G. de Girolamo, J. A. Costa e Silva, Y. Lecrubier & H.-U. Wittchen (Eds), Psychological Disorders in General Medical Settings (pp. 159-169). Toronto, Canada: Hogrefe & Huber.
38. White, K. S., & Barlow, D. H. (2002). Panic disorder and agoraphobia. In D. H. Barlow (Ed.). Anxiety and Its Disorders: The Nature and Treatment of Anxiety and Panic (2nd edn) (pp. 328-379). New York: Guilford Press.
39. Wittchen, H.-U. (1998). Recognition and management of anxiety syndromes. British Journal of Psychiatry, 173(suppl. 34), 1-3.